world congress

delivering therapies to the clinic faster

Monday, September 23

8:30 - 9:00 a.m.	**Introduction and Welcome Remarks** James C. Foster, *Chairman of the Board, President, and Chief Executive Officer, Charles River*
9:00 - 9:30 a.m.	**2019 Award Winner: A Silicon Valley Approach to Understanding and Treating Disease** Matt Wilsey, *Chairman, President, and Co-Founder, Grace Science Foundation*
9:30 - 10:15 a.m.	**Keynote Session** Brian Hubbard, PhD, *Chief Executive Officer, Dogma Therapeutics*
10:15 - 10:30 a.m.	**Break**
10:30 - 11:15 a.m.	**Novel Approaches to Silence Disease Drivers Systemic Delivery of Investigational RNAi Therapeutics: Safety Considerations and Clinical Outcomes** Peter Smith, PhD, *Senior Vice President, Early Development, Alnylam Pharmaceuticals*
11:15 a.m. - 12:00 p.m.	**Novel Approaches to Silence Disease Drivers: Considerations for Viral Vector Manufacturing to Support Product Commercialization** Richard Snyder, PhD, *Chief Scientific Officer and Founder, Brammer Bio*
12:00 - 1:00 p.m.	**Lunch**
1:00 - 1:45 p.m.	**Accelerating Drug Discovery Through the Power of Microscopy Images** Anne E. Carpenter, Ph.D., *Institute Scientist, Sr. Director, Imaging Platform, Merkin Institute Fellow, Broad Institute of Harvard and MIT*
1:45 - 2:30 p.m.	**The Role of AI in Expediting Drug Discovery Target Identification for Nonalcoholic Steatohepatitis Using Machine Learning: The Case for nference** Venky Soundararajan, PhD, *Founder and Chief Scientific Officer, nference/Qrativ*
2:30 - 2:45 p.m.	**Break**
2:45 - 3:30 p.m.	**Technobite Sessions with Emulate Bio and University of Pittsburgh Drug Discovery Institute**
3:30 - 4:15 p.m.	**Artificial Intelligence Panel Discussion: Real World Applications from Discovery to Clinic** Moderated by Carey Goldberg, *WBUR*
4:15 - 4:45 p.m.	**Jack's Journey** Jake and Elizabeth Burke, *Cure NF with Jack*
4:45 - 5:00 p.m.	**Closing Remarks**
5:00 - 6:00 p.m.	**Networking Reception**

world congress

delivering therapies to the clinic faster

Tuesday, September 24

8:45 - 9:00 a.m.	**Opening Remarks and Recap** James C. Foster, *Chairman of the Board, President, and Chief Executive Officer, Charles River*
9:00 - 9:30 a.m.	**2018 Award Winner Update** David Hysong, *Patient Founder and Chief Executive Officer, Shepherd Therapeutics* William Siders, *CDO, Shepherd Therapeutics*
9:30 - 10:15 a.m.	**Advances in Human Genetics and Therapeutic Modalities Enable Novel Therapies** Eric Green, *Vice President of Research and Development, Maze Therapeutics*
10:15 - 11:00 a.m.	**How Genomics is Expediting Drug Discovery** Manuel Rivas, *Assistant Professor, Department of Biomedical Data Science, Stanford University*
11:00 - 11:15 a.m.	**Break**
11:15 a.m. - 12:00 p.m.	**Genomics Panel Discussion: Signposting Targets That Will Speed the Path to Market** Moderated by Martin Mackay, *Co-Founder, RallyBio*
12:00 - 1:00 p.m.	**Lunch**
1:00 - 1:45 p.m	**Truly Personalized Medicines for Ultra-rare Diseases: New Opportunities in Genomic Medicine** Timothy Yu, *Attending Physician, Division of Genetics and Genomics and Assistant Professor in Pediatrics, Boston Children's Hospital*
1:45 - 2:30 p.m.	**Application of Machine Learning Technology for the Assessment of Bulbar Symptoms in ALS** Fernando Vieira, *Chief Scientific Officer, ALS Therapy Development Institute*
2:30 - 2:45 p.m.	**Break**
2:45 - 3:30 p.m.	**Accelerating Rare Disease Therapies Through the Regulatory Process** Martine Zimmermann, *Senior Vice President and Head of Global Regulatory Affairs, Alexion Pharmaceuticals, Inc.*
3:30 - 4:00 p.m.	**Wearing ALL the Hats: From Impossible to Possible** Allyson Berent, *Chief Operating Officer, GeneTx Biotherapeutics*
4:00 - 4:15 p.m.	**Closing Remarks**